Strong Efficacy of Ritlecitinib 50 mg and Baricitinib 4 mg in Alopecia Areata, but Further Research Needed to Establish Superiority

The study highlights the strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in treating alopecia areata (AA), with both drugs showing significant hair regrowth at Week 24. Despite the promising results, no significant difference was found between the two treatments on key endpoints, except for a slight advantage of ritlecitinib over baricitinib 2 mg in achieving SALT ≤20. The study notes the challenge of interpreting data due to differing sample sizes, with only 118 patients receiving ritlecitinib compared to nearly 900 for baricitinib. The authors emphasize the need for direct, head-to-head clinical trials to determine the most effective treatment for AA. The study underscores the importance of JAK inhibitors in expanding treatment options and improving personalized care for patients with AA.